Literature DB >> 27710965

The Role of Biogenic Amines in the Regulation of Interaction between the Immune and Nervous Systems in Multiple Sclerosis.

Alexey Boyko1, Mikhail Melnikov, Rustam Zhetishev, Mikhail Pashenkov.   

Abstract

OBJECTIVE: Multiple sclerosis (MS) is a demyelinating, presumably autoimmune disease of the central nervous system. Biogenic amines may participate in MS pathogenesis modulating immune cell activity and cytokine production.
METHODS: Forty-three patients with relapsing-remitting MS were examined. Serotonin (SE), norepinephrine (NE) and epinephrine (EPI) concentrations in sera were measured by ELISA. The functional activity of Th17 and Th1 cells was assessed by the ability of peripheral blood mononuclear cells (PBMCs) to produce interferon-gamma (IFN-γ) and interleukin-17 (IL-17) and cell proliferation upon stimulation with microbeads coated with anti-CD3 and anti-CD28 antibodies. To evaluate the effect of biogenic amines on Th17 and Th1 cells, PBMCs were cultured in the presence of SE and NE. Statistical analysis was performed using Prism 6 software.
RESULTS: Concentrations of SE and EPI in sera were not different between the groups. Concentrations of NE in sera from MS patients were lower than those in the healthy control group. The production of IL-17 and IFN-γ in MS patients in relapse was higher than that in patients in remission or in the control group. SE at a concentration of 10-4M suppressed IL-17 production. NE at a concentration of 10-4M suppressed both IL-17 and IFN-γ production.
CONCLUSIONS: These data suggest an anti-inflammatory role for biogenic amines in MS.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27710965     DOI: 10.1159/000449167

Source DB:  PubMed          Journal:  Neuroimmunomodulation        ISSN: 1021-7401            Impact factor:   2.492


  5 in total

Review 1.  Dopaminergic Therapeutics in Multiple Sclerosis: Focus on Th17-Cell Functions.

Authors:  Mikhail Melnikov; Vladimir Rogovskii; Alexey Boykо; Mikhail Pashenkov
Journal:  J Neuroimmune Pharmacol       Date:  2019-04-23       Impact factor: 4.147

2.  Changes of central noradrenaline transporter availability in immunotherapy-naïve multiple sclerosis patients.

Authors:  Elisa Schmidt; Christian Schinke; Michael Rullmann; Julia Luthardt; Georg-Alexander Becker; Sarah Haars; Muriel Stoppe; Donald Lobsien; Karl-Titus Hoffmann; Osama Sabri; Swen Hesse; Florian Then Bergh
Journal:  Sci Rep       Date:  2020-09-04       Impact factor: 4.379

Review 3.  Multiple Sclerosis and Serotonin: Potential Therapeutic Applications.

Authors:  Aleyda M San Hernandez; Chetana Singh; Danel J Valero; Javariya Nisar; Jose I Trujillo Ramirez; Karisma K Kothari; Sasank Isola; Domonick K Gordon
Journal:  Cureus       Date:  2020-11-02

Review 4.  α-Synuclein and Noradrenergic Modulation of Immune Cells in Parkinson's Disease Pathogenesis.

Authors:  Laura M Butkovich; Madelyn C Houser; Malú G Tansey
Journal:  Front Neurosci       Date:  2018-09-11       Impact factor: 4.677

5.  The Dual Role of the β2-Adrenoreceptor in the Modulation of IL-17 and IFN-γ Production by T Cells in Multiple Sclerosis.

Authors:  Mikhail Melnikov; Vladimir Rogovskii; Anastasiya Sviridova; Anna Lopatina; Mikhail Pashenkov; Alexey Boyko
Journal:  Int J Mol Sci       Date:  2022-01-08       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.